Atlas Trials

Study to Find the Highest Safe Dose of Soluble Guanylate Cyclase (sGC) Activator, BAY 1211163 Administered as Multiple Doses by Inhalation to Patients Who Cannot Breathe by Their Own and Suffer From a Type of Lung Failure That Causes Fluid to Build up in the Lungs Making Breathing Difficult (ARDS)

Clinical trial NCT04609943 · TERMINATED

Trial details

NCT number
NCT04609943
Sponsor
Bayer
Status
TERMINATED
Phase
Phase 1
Study type
INTERVENTIONAL
Acute Respiratory Distress Syndrome
Start date
2020-11-24
Primary completion
2023-08-17
Enrollment
16

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.